12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vosaroxin regulatory update

The European Commission granted Orphan Drug designation for Sunesis' vosaroxin to treat acute myelogenous leukemia (AML). Vosaroxin is in the Phase III VALOR trial in...

Read the full 102 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >